Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy

Rheumatology International

Volumn 32, Issue 6, 2012, Pages 1647-1653

  McGeough, Cathy M ^a   Berrar, Daniel ^a   Wright, Gary ^b   Mathews, Clare ^b   Gilmore, Paula ^c   Cunningham, Rodat T ^c   Bjourson, Anthony J ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b MUSGRAVE PARK HOSPITAL   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Anti TNF lpha therapy; Genotype; Human leukocyte antigen C; Killer immunoglobulin like receptor; Natural killer cells; Responder; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; HLA C ANTIGEN; INFLIXIMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; METHOTREXATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HETEROZYGOTE; HLA-C ANTIGENS; HOMOZYGOTE; HUMANS; IMMUNOGLOBULIN G; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; NORTHERN IRELAND; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTORS, KIR; RECEPTORS, KIR2DL2; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863880925     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1838-6     Document Type: Article

References (43)

1. Suto Y, Maenaka K, Yabe T, Hirai M, Tokunaga K, Tadok K et al (1996) Chromosomal localisation of the human natural killer cell class I receptor family genes to 19q13.4 by fluorescence in situ hybridisation. Genomics 35:270-272
2. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N (1998) Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol 161:571-577
3. Valéz-Gómez M, Reyburn HT, Erskine RA, Stominger J (1998) Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci USA 95:14326-14331
4. Carrington M, Martin MP (2006) The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immmunol 298:225-257
5. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ et al (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nature Genet 31:429-434
6. Jennes W, Verhryden S, Demanet C, Adjé-Toure CA, Vuylsteke B, Nkengasong JN et al (2006) Cutting edge: resistance to HIV-1 infection among African Female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 177:6588-6592
7. Kakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J et al (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C infection. Science 305:872-874
8. Hollenbach JA, Ladner MB, Saeteurn K, Taylor KD, Mei L, Haritunians T et al (2009) Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand. Immunogenetics 61:633-671
9. Zhang HX, Li JC, Liu ZJ (2008) Relationship between expression of inhibitory killer cell immunoglobulin-like receptor HLACw ligand and susceptibility to inflammatory bowel disease. Zhonghua Yi Xue Za Zhi 88:3108-3111
10. Wilson TJ, Jobin M, Jobin LF, Portela P, Salim PH, Rosito MA et al (2010) Study of killer immunoglobulin-like receptor genes and human leukocyte antigens class I ligands in a Caucasian Brazilian population with Crohn's disease and ulcerative colitis. Hum Immunol 71:293-297
11. Jones DC, Edgar RS, Ahmad T, Cummings JR, Jewell DP, Trowsdale J et al (2006) Killer Ig-like receptor genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immun 7:576-582
12. Ho YF, Zhang YC, Jiao YL, Wang LC, Li JF, Pan ZL et al (2010) Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus. Lupus 19:20-26
13. Pellett F, Siannis F, Vukin I, Lee P, Urowitz MB, Gladmann DD (2007) KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens 69(Suppl 1):106-108
14. Van der slik AR, Koeleman BP, Verduijn W, Bruining GJ, Roep BO, Giphart MJ (2003) KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 52:2639-2642
15. Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M (2004) Heterozygote advantage in autoimmune disease: hierarchy of protection/ susceptibility conferred by HLA and killer Ig-like receptor combinations in Psoriatic arthritis. J Immunol 173:4273-4276
16. Namekawa T, Snyder MR, Yen JH, Goehring BE, Liebson PJ, Weyand CM et al (2000) Killer cell activating receptors function as costimulatory molecules on CD4?CD28null T-cells clonally expanded in rheumatoid arthritis. J Immunol 165:1138-1145
17. Martens PB, Goronzy JJ, Schaid D, Weyand CM (1997) Expansion of unusual CD4? T cells in severe rheumatoid arthritis. Arthritis Rheum 40:1106-1114
18. Majorczyk E, Pawlik A, Łuszczek W, Nowak I, Wis'niewski A, Jasek M et al (2007) Associations of killer cell immunoglobulinlike receptor genes with complications of rheumatoid arthritis. Genes Immun 8:678-683
19. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM et al (2001) Major histocompatibility complex class-I recognising receptors are disease risk genes in rheumatoid arthritis. J Exp Med 193:1159-1167
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
21. Prevoo ML, van't Hof MA, Kuper HH, van Leeuween MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
22. British Society for Rheumatology (2001) Guidelines for prescribing TNF-blockers in adults with rheumatoid arthritis. http://www.rheumatology.org. uk/guidelines/clinicalguidelines. Accessed 21 Apr 2010
23. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
24. Middleton D, Williams F, Halfpenny IA (2005) KIR genes. Transpl Immunol 14:135-142
25. Cereb N, Maye P, Lee S, Kong Y, Yang SY (1995) Locus specific amplification of HLA class I genes from genomic DNA: locus specific sequences in the first and third introns of HLA-A, -B, and C alleles. Tissue Antigens 45:1-11
26. Williams F, Meenagh A, Patterson C, Middleton D (2002) Molecular diversity of the HLA-C gene identified in a Caucasian population. Hum Immunol 63:602-613
27. Ringnér M, Edén P, Johansson P (2003) Classification of expression patterns using artificial neural networks. In: Berrar D, Dubitzky W, Granzow M (eds) A practical approach to microarray data analysis. Kluwer Academic, Boston/Dordrecht/London
28. Takeda K, Dennert G (1993) The development of autoimmunity in C57BL/6 mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 117:155-164
29. Neighbour PA, Grayzel AI, Miller AE (1982) Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol 49:11-21
30. Armstrong RD, Panayi GS (1983) Natural killer cell activity in inflammatory joint disease. Clin Rheumatol 2:243-249
31. Combe B, Pope R, Darnell B, Talal N (1984) Modulation of natural killer cell activity in the rheumatoid joint and peripheral blood. Scand J Immunol 20:551-558
32. Karsh J, Dorval G, Osterland CK (1981) Natural cytotoxicity in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 19:437-446
33. Aramaki T, Ida H, Izumi Y, Fujikawa K, Huang M, Arima K et al (2009) A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod Rheumatol 19:245-252
34. Boyton RJ, Smith J, Ward R, JonesM, Ozerovitch L, Wilson R et al (2006) HLA-C and killer cell immunoglobulin-like receptors in idiopathic bronchiectasis. Am J Resp Crit Care Med 173:327-333
35. Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE et al (2004) Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 50:1561-1565
36. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D (2003) Polymorphism at position -308 of the tumour necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 48:1849-1852
37. Balog A, Klausz G, Gál J, Molnár T, Nagy F, Ocksovszky I et al (2004) Investigation of the prognostic value of TNF-αlpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-αlpha production and apoptosis. Pathobiology 71:274-280
38. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J et al (2004) The influence of genetic variation in the HLA-DRB1 and ltA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 50:2750-2756
39. Martinez A, Salido M, Bonilla G, Pascual-Salcedo D, Fernandez-Arguero M, de Miguel S et al (2004) Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 50:1077-1082
40. Pavy S, Toonen EJ, Miceili-Richard C, Barrera P, van Reil PL, Criswell LA et al (2010) Tumour necrosis factor alpha-308G-[A polymorphism is not associated with response to TNF alpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 69:1022-1028
41. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL et al (2008) Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis 67:563-566
42. Hueber W, Tomooka BH, Baltliwalla F, Li W, Monach PA, Tibshirani RJ et al (2009) Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 11:R76
43. Badot V, Galant C, Nzeusseu Toukap A, Theate I, Maudoux AL, Van den Eynde BJ et al (2009) Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther 11:R57